OWC Pharmaceutical Research (OWCP) Stock Statistics & Valuation Metrics
Total Valuation
OWC Pharmaceutical Research has a market cap or net worth of $497.00. The enterprise value is -$3.46T.
- Market Cap
- $497.00
- Enterprise Value
- -$3.46T
Share Statistics
OWC Pharmaceutical Research has 497,498,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 497,498,350
- Owned by Insiders
- ―
- Owned by Institutions
- 0.01%
Financial Efficiency
OWC Pharmaceutical Research’s return on equity (ROE) is 1.09 and return on invested capital (ROIC) is -137.91%.
- Return on Equity (ROE)
- 1.09
- Return on Assets (ROA)
- -2.89
- Return on Invested Capital (ROIC)
- -137.91%
- Return on Capital Employed (ROCE)
- -1.38
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.14M
- Employee Count
- 9
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of OWC Pharmaceutical Research is -0.00. OWC Pharmaceutical Research’s PEG ratio is -0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.00
- PB Ratio
- -0.00
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.00
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, OWC Pharmaceutical Research had revenue of 0 and earned -10.26M in profits. Earnings per share was -0.07.
- Revenue
- 0
- Gross Profit
- ―
- Operating Income
- -4.30M
- Pretax Income
- -10.26M
- Net Income
- -10.26M
- EBITDA
- -3.56M
- Earnings Per Share (EPS)
- -0.07
Cash Flow
In the last 12 months, operating cash flow was -2.74M and capital expenditures -7,035, giving a free cash flow of -2.75M billion.
- Operating Cash Flow
- -2.74M
- Free Cash Flow
- -2.75M
- Free Cash Flow per Share
- -0.02
Dividends & Yields
OWC Pharmaceutical Research pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -50793.97%
- Earnings Yield
- -692797.35%
Stock Price Statistics
- Beta
- -3.79
- 52-Week Price Change
- -99.99%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
OWC Pharmaceutical Research as a current ratio of 8.03, with Debt / Equity ratio of 0.00%
- Current Ratio
- 8.03
- Quick Ratio
- 8.03
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.97
- Interest Coverage Ratio
- -1432.00
Taxes
In the past 12 months, OWC Pharmaceutical Research has paid 3,000 in taxes.
- Income Tax
- 3,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
OWC Pharmaceutical Research EV to EBITDA ratio is 0.97, with an EV/FCF ratio of 1.37.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.97
- EV to Free Cash Flow
- 1.37
- EV to Operating Cash Flow
- 1.38
Balance Sheet
OWC Pharmaceutical Research has $1.47M in cash and marketable securities with $47.00K in debt, giving a net cash position of $1.42M billion.
- Cash & Marketable Securities
- $1.47M
- Total Debt
- $47.00K
- Net Cash
- $1.42M
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- -$0.02
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for OWC Pharmaceutical Research is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―